Persistent Chronic Inflammation Contributes to the Development of Cancer in Patients with Rheumatoid Arthritis from a Defined Population of Northwestern Spain

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 1, 2007, Pages 31-38

  Llorca, Javier ^a   Lopez Diaz, Maria J ^b   Gonzalez Juanatey, Carlos ^b   Ollier, William E R ^c   Martin, Javier ^d   Gonzalez Gay, Miguel A ^b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

cancer; comorbidity; genetics; inflammation; mortality; rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; HLA DR ANTIGEN; METHOTREXATE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CAUSE OF DEATH; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT DEPARTMENT; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX DIFFERENCE; SPAIN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 34447629240     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.01.002     Document Type: Article

References (52)

1. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., and Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60 (2001) 433-441
2. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
3. Ekstrom K., Hjalgrim H., Brandt L., Baecklund E., Klareskog L., Ekbom A., et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48 (2003) 963-970
4. Franklin J., Lunt M., Bunn D., Symmons D., and Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65 (2006) 617-622
5. Hakulinen T., Isomaki H., and Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 78 (1985) 29-32
6. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., Gregersen H., Porwit-MacDonald A., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98 (2006) 51-60
7. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165 (2005) 2337-2344
8. Cuttner J., Spiera H., Troy K., and Wallenstein S. Autoimmune disease is a risk factor for the development of non-Hodgkin's lymphoma. J Rheumatol 32 (2005) 1884-1887
9. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
10. Baltus J.A., Boersma J.W., Hartman A.P., and Vandenbroucke J.P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 42 (1983) 368-373
11. Radis C.D., Kahl L.E., Baker G.L., Wasko M.C., Cash J.M., Gallatin A., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 38 (1995) 1120-1127
12. Gonzalez-Gay M.A., Garcia-Porrua C., and Hajeer A.H. The HLA-DRB1 influence in the susceptibility and severity to rheumatoid arthritis. Semin Arthritis Rheum 31 (2002) 355-360
13. Gregersen P.K., Silver J., and Winchester R.J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987) 1205-1213
14. Ollier W., Venables P.J.W., Mumford P.A., Maini R.N., Awad J., Jaraquemada D., et al. HLA antigen associations with extra-articular rheumatoid arthritis. Tissue Antigens 24 (1984) 279-291
15. Perdriger A., Chales G., Semana G., Guggenbuhl P., Meyer O., Quillivic F., et al. Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis. J Rheumatol 24 (1997) 1272-1276
16. Salvarani C., Macchioni P., Mantovani W., Rossi F., Veneziani M., Boiardi L., et al. Extraarticular manifestations of rheumatoid arthritis and HLA antigens in Northern Italy. J Rheumatol 19 (1992) 242-246
17. Weyand C.M., Xie C., and Goronzy J.J. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 89 (1992) 2033-2039
18. Gonzalez-Gay M.A., Gonzalez-Juanatey C., and Ollier W.E. Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun Rev 3 (2004) 301-304
19. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Vidan J., et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114 (2003) 647-652
20. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., Pĩneiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007) 125-132
21. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
22. Dababneh A., Gonzalez-Gay M.A., Garcia-Porrua C., Hajeer A., Thomson W., and Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 25 (1998) 2140-2145
23. Gonzalez-Gay M.A., Alonso M.D., Aguero J.J., Bal M., Fernandez-Camblor B., and Sanchez-Andrade A. Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. J Rheumatol 19 (1992) 277-280
24. Gonzalez-Gay M.A., and Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 78 (1999) 292-308
25. Gonzalez-Gay M.A., Garcia-Porrua C., Guerrero J., Rodriguez-Ledo P., and Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 49 (2003) 388-393
26. Gonzalez-Juanatey C., Llorca J., Testa A., Revuelta J., Garcia-Porrua C., and Gonzalez-Gay M.A. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82 (2003) 407-413
27. Gonzalez-Gay M.A., Garcia-Porrua C., Pĩneiro A., Pego-Reigosa A., Llorca J., and Hunder G.G. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 83 (2004) 335-341
28. Hajeer A.H., Dababneh A., Makki R.F., Thomson W., Poulton K., Gonzalez-Gay M.A., et al. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens 55 (2000) 319-325
29. Klareskog L., Stolt P., Lundberg K., Kallberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54 (2006) 38-46
30. Leandro M.J., and Isenberg D.A. Rheumatic diseases and malignancy-is there an association?. Scand J Rheumatol 30 (2001) 185-188
31. Banks P.M., Witrak G.A., and Conn D.L. Lymphoid neoplasia following connective tissue disease. Mayo Clin Proc 54 (1979) 104-108
32. Isomaki H.A., Hakulinen T., and Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31 (1978) 691-696
33. Katusic S., Beard C.M., Kurland L.T., Weis J.W., and Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 78 (1985) 50-55
34. Myllykangas-Luosujarvi R., Aho K., and Isomaki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 24 (1995) 76-78
35. Symmons D.P., Ahern M., Bacon P.A., Hawkins C.F., Amlot P.L., Jones E.L., et al. Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis 43 (1984) 132-135
36. Tennis P., Andrews E., Bombardier C., Wang Y., Strand L., West R., et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol 46 (1993) 685-695
37. Sihvonen S., Korpela M., Laippala P., Mustonen J., and Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 33 (2004) 221-227
38. Riise T., Jacobsen B.K., Gran J.T., Haga H.J., and Arnesen E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 20 (2001) 123-127
39. Cibere J., Sibley J., and Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40 (1997) 1580-1586
40. Fries J.F., Bloch D., Spitz P., and Mitchell D.M. Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 78 (1985) 56-59
41. Mikuls T.R., Saag K.G., Criswell L.A., Merlino L.A., Kaslow R.A., Shelton B.J., et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 61 (2002) 994-999
42. Thomas E., Symmons D.P., Brewster D.H., Black R.J., and Macfarlane G.J. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. J Rheumatol 30 (2003) 958-965
43. Dessein P.H., Stanwix A.E., and Joffe B.I. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4 (2002) R5
44. Gonzalez-Gay M.A., Gonzalez-Juanatey C., and Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35 (2005) 8-17
45. Sattar N., McCarey D.W., Capell H., and McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003) 2957-2963
46. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32 (2005) 435-442
47. Del Rincon I., Williams K., Stern M.P., Freeman G.L., O'Leary D.H., and Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48 (2003) 1833-1840
48. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A., Garcia-Porrua C., Testa A., and Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1219-1223
49. Wolfe F. Inflammatory activity but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis. A 25 year study of 1,767 RA patients. Arthritis Rheum 41 Suppl 9 (1998) 188
50. Sattar N., and McInnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17 (2005) 286-292
51. Bologna C., Picot M.C., Jorgensen C., Viu P., Verdier R., and Sany J. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 56 (1997) 97-102
52. Moder K.G., Tefferi A., Cohen M.D., Menke D.M., and Luthra H.S. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99 (1995) 276-281